{"id":26,"date":"2008-05-05T17:46:05","date_gmt":"2008-05-05T21:46:05","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/cto\/melanoma\/"},"modified":"2021-09-03T11:02:10","modified_gmt":"2021-09-03T15:02:10","slug":"cutaneous","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/hematology-and-oncology-clinical-trials-2\/cutaneous\/","title":{"rendered":"Cutaneous Cancer &#8211; Extra Long URL"},"content":{"rendered":"<h4>Melanoma:<\/h4>\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03698019?term=s1801&amp;rank=1\"><strong>CIRB #H-38640\/ SWOG #S1801<\/strong>: <\/a>A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant\u00a0 Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma<\/p>\n<p><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04462406?term=NCT04462406&#038;draw=2&#038;rank=1\"><strong>CIRB #H-41279\/ CTSU #EA6191 (PET-stop)<\/strong>: <\/a>A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) <b> (pending) <\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Melanoma: CIRB #H-38640\/ SWOG #S1801: A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant\u00a0 Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma CIRB #H-41279\/ CTSU #EA6191 (PET-stop): A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop) (pending)<\/p>\n","protected":false},"author":1006,"featured_media":0,"parent":1824,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/26"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/users\/1006"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/comments?post=26"}],"version-history":[{"count":50,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/26\/revisions"}],"predecessor-version":[{"id":5183,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/26\/revisions\/5183"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/pages\/1824"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/clinicaltrials\/wp-json\/wp\/v2\/media?parent=26"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}